AZN
AstraZeneca PLC

18,864
Mkt Cap
$316.61B
Volume
1.59M
52W High
$212.71
52W Low
$122.48
PE Ratio
30.96
AZN Fundamentals
Price
$204.20
Prev Close
$206.45
Open
$206.60
50D MA
$188.56
Beta
0.40
Avg. Volume
4.72M
EPS (Annual)
$6.60
P/B
6.90
Rev/Employee
$622,895.02
$313,656.50
Loading...
Loading...
News
all
press releases
AstraZeneca PLC (LON:AZN) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of AstraZeneca PLC (LON:AZN - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. One...
MarketBeat·23h ago
News Placeholder
More News
News Placeholder
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Zacks·2d ago
News Placeholder
Woodley Farra Manion Portfolio Management Inc. Lowers Holdings in AstraZeneca PLC $AZN
Woodley Farra Manion Portfolio Management Inc. lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 1.0% in the 3rd quarter, according to its most recent 13F filing with the...
MarketBeat·2d ago
News Placeholder
AstraZeneca PLC $AZN Shares Purchased by Synovus Financial Corp
Synovus Financial Corp grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 10.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·2d ago
News Placeholder
Wealthcare Advisory Partners LLC Buys 19,612 Shares of AstraZeneca PLC $AZN
Wealthcare Advisory Partners LLC boosted its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 558.1% during the 3rd quarter, according to the company in its most recent filing with the...
MarketBeat·2d ago
News Placeholder
CALQUENCE plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
AstraZenecas CALQUENCE (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic...
Business Wire·2d ago
<
...
1
>

Latest AZN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.